BiotechTube

XEN1101 + Placebo

Phase 3Recruiting
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Focal Onset Seizures

Conditions

Focal Onset Seizures

Trial Timeline

May 9, 2023 → Dec 1, 2026

NCT ID
NCT05716100

About XEN1101 + Placebo

XEN1101 + Placebo is a phase 3 stage product being developed by Xenon Pharmaceuticals for Focal Onset Seizures. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05716100. Target conditions include Focal Onset Seizures.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT05716100Phase 3Recruiting
NCT05667142Phase 3Recruiting
NCT05614063Phase 3Completed

Competing Products

20 competing products in Focal Onset Seizures

See all competitors
ProductCompanyStageHype Score
OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved
85
DapagliflozinAstraZenecaApproved
85
Enfuvirtide + Tenofovir-EmtricitabineRochePhase 2
52
CCX140-BAmgenPhase 2
51
PF-06730512PfizerPhase 2
51
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, ZonisamidePfizerApproved
84
VX-147Vertex PharmaceuticalsPhase 2
51
VX-147Vertex PharmaceuticalsPhase 1
32
IXPVertex PharmaceuticalsPhase 1
32
fresolimumab + fresolimumab + PlaceboSanofiPhase 2
51
GC1008 + GC1008 + GC1008 + GC1008SanofiPhase 1
32
frexalimab + brivekimig + rilzabrutinib + placeboSanofiPhase 2
51
VivaglobinCSLPhase 2
51
UCB0942UCBPhase 2
49
Levetiracetam + Carbamazepine + LamotrigineUCBApproved
82
Brivaracetam + BrivaracetamUCBPhase 2
49
LacosamideUCBPhase 2
49
UCB0942 + UCB0942 + PlaceboUCBPhase 2
49
LacosamideUCBPre-clinical
20
ARGX-117ArgenxPhase 2
49

Other Products from Xenon Pharmaceuticals

XEN496Phase 3
74
XEN1101 + PlaceboPhase 3
74
XEN1101 + PlaceboPhase 3
74
AzetukalnerPhase 3
74
XEN496 + PlaceboPhase 3
74